Sinovac Biotech, Ltd (SVA) Posts Q2 Loss of 4c/Share

Sinovac Biotech, Ltd (NASDAQ: SVA) reported Q2 EPS of ($0.04), $0.04 worse than the analyst estimate of $0.00. Revenue for the quarter came in at $12.1 million versus the consensus estimate of $17.2 million.

For earnings history and earnings-related data on Sinovac Biotech, Ltd (SVA) click here.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• Data I/o Corp (DAIO) Misses Q2 EPS by 7c
• Allison Transmission (ALSN) Tops Q1 EPS by 2c, Beats on Revenue; Offers FY24 Revenue Guidance